Mirae Asset Global Investments Co. Ltd. boosted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 38.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 406,467 shares of the company's stock after purchasing an additional 113,157 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Kenvue were worth $8,677,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also added to or reduced their stakes in the company. AMF Tjanstepension AB raised its holdings in shares of Kenvue by 187.3% in the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company's stock valued at $2,787,000 after acquiring an additional 78,540 shares in the last quarter. Mather Group LLC. raised its holdings in shares of Kenvue by 62.0% in the 3rd quarter. Mather Group LLC. now owns 6,857 shares of the company's stock valued at $159,000 after acquiring an additional 2,625 shares in the last quarter. Atomi Financial Group Inc. purchased a new stake in shares of Kenvue in the 3rd quarter valued at about $212,000. Perpetual Ltd raised its holdings in shares of Kenvue by 2.6% in the 3rd quarter. Perpetual Ltd now owns 25,380 shares of the company's stock valued at $587,000 after acquiring an additional 652 shares in the last quarter. Finally, Juncture Wealth Strategies LLC purchased a new stake in shares of Kenvue in the 3rd quarter valued at about $241,000. Institutional investors own 97.64% of the company's stock.
Analysts Set New Price Targets
Several research firms have weighed in on KVUE. Bank of America raised their price target on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, October 22nd. Barclays decreased their price objective on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a report on Friday, January 17th. Citigroup decreased their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday, January 15th. UBS Group decreased their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday. Finally, Canaccord Genuity Group decreased their price objective on Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $23.00.
Check Out Our Latest Analysis on Kenvue
Kenvue Trading Up 1.7 %
Kenvue stock traded up $0.35 during trading hours on Tuesday, reaching $20.93. The company had a trading volume of 10,921,780 shares, compared to its average volume of 12,761,109. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a 50-day moving average price of $21.46 and a 200 day moving average price of $22.02. The firm has a market cap of $40.13 billion, a price-to-earnings ratio of 39.49, a P/E/G ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts forecast that Kenvue Inc. will post 1.05 earnings per share for the current year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.92%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's payout ratio is 154.72%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
